Veeva Launches eSource to Automate Clinical Data Capture, UBS Cuts Target to $200
Veeva launched eSource on January 29 within its SiteVault platform to enable direct digital capture at research sites, integrate EHR and EDC systems, eliminate paper-based processes, reduce administrative burden, decrease errors and accelerate clinical trials. UBS cut Veeva’s price target to $200 from $280 while maintaining a Neutral rating.
1. eSource Launch Announcement
Veeva launched its new eSource application on January 29 as part of the SiteVault platform to digitize clinical trial source data capture.
2. Key Features and Benefits
The solution enables direct digital data entry at trial sites, integrates electronic health records with electronic data capture systems, eliminates paper-based workflows and source data verification, and reduces administrative burden and error rates.
3. Availability Timeline
eSource features open API connectivity and is slated for early adopter rollout in the second half of 2026, aiming to accelerate study execution and improve data accuracy.
4. UBS Price Target Revision
UBS revised its price target on Veeva from $280 to $200 and maintained a Neutral rating, reflecting adjusted near-term expectations.